Dichloromethane fractions of Calystegia soldanella induce S-phase arrest and apoptosis in HT-29 human colorectal cancer cells

IN-HYE KIM1*, TAEKIL EOM1*, JOON-YOUNG PARK2, HYUNG-JOO KIM1 and TAEK-JEONG NAM1

1Future Fisheries Food Research Center, Institute of Fisheries Sciences, Pukyong National University, Busan 46041; 2Department of Food Science and Nutrition, Pukyong National University, Busan 48513, Republic of Korea

Received September 8, 2021; Accepted November 11, 2021

DOI: 10.3892/mmr.2021.12576

Abstract. Calystegia soldanella is a halophyte and a perennial herb that grows on coastal sand dunes worldwide. Extracts from this plant have been previously revealed to have a variety of bioactive properties in humans. However, their effects on colorectal cancer cells remain poorly understood. In the present study, the potential biological activity of C. soldanella extracts in the colorectal cancer cell line HT-29 was examined. First, five solvent fractions [n-hexane, dichloromethane (DCM), ethyl acetate, n-butanol and water] were obtained from the crude extracts of C. soldanella through an organic solvent extraction method. In particular, the DCM fraction was demonstrated to exert marked dose- and time-dependent inhibitory effects according to results from the cell viability assay. Data obtained from the apoptosis assay suggested that the inhibition of HT-29 cell viability induced by DCM treatment was attributed to increased apoptosis. The apoptotic rate was markedly increased in a dose-dependent manner, which was associated with the protein expression levels of apoptosis-related proteins, including increased Fas, Bad and Bax, and decreased pro-caspase-8, Bcl-2, Bcl-xl, pro-caspase-9, pro-caspase-7 and pro-caspase-3. A mitochondrial membrane potential demonstration that more cells became depolarized and the extent of cytochrome c release was markedly increased in a dose-dependent manner in HT-29 cells treated with DCM. In addition, cell cycle analysis confirmed S-phase arrest following DCM fraction treatment, which was associated with decreased protein expression levels of cell cycle-related proteins, such as cyclin A, CDK2, cell division cycle 25 A and cyclin dependent kinase inhibitor 1. Based on these results, the present study suggested that the DCM fraction of the C. soldanella extract can inhibit HT-29 cell viability whilst inducing apoptosis through mitochondrial membrane potential regulation and S-phase arrest. These results also suggested that the DCM fraction has potential anticancer activity in HT-29 colorectal cells. Further research on the composition of the DCM fraction is warranted.

Introduction

Colorectal cancer is prevalent and a leading cause of death worldwide (1). The mortality rate of colorectal cancer has been declining over the past number of decades due to early diagnosis using improved screening and treatment strategies. However, the incidence remains high (2). Over the past several decades, in the United States, the incidence and mortality rates of colorectal cancer have been steadily decreasing among those aged >50 years, but the number of those aged between 20 and 49 years is increasing. It is estimated that the incidence and mortality rates of colorectal cancer according to these age groups increase uniformly with economic development due to environmental changes, such as lifestyle, increased obesity and overall lifespan extension, and the consumption of processed foods, alcohol and meat (1,2). To date, colorectal cancer treatment involves radiotherapy and traditional therapies, including surgery and chemotherapy (3). However, these treatments are limited by toxicity, adverse events and drug resistance (3). A number of studies have previously reported that colorectal and colon cancer is negatively associated with dietary factors, including plants, seaweeds, vegetables and fruits, which contain a variety of phytochemicals (4-6). These phytochemicals have been demonstrated to protect cells from damage that leads to cancer (7-13).

The halophyte Calystegia soldanella (Linnaeus) Roem. et Schult (Convolulaceae) is a perennial herb that grows on coastal sand dunes worldwide (14). This plant has been extensively used in traditional medicine for general consumption and as a type of herbal treatment, since it is considered to confer bioactive effects against rheumatic arthritis, sore throat, dyspy, scurvy, fever and diarrhea (15-17). In particular, fractions of C. soldanella have been reported to exhibit anti-inflammatory (18-20), antifungal (21), antiviral (22-25), anticancer (26,27) and analgesic effects (28). Although the various bioactivities of C. soldanella have been assessed, its effects on colon cancer have not been explored.
In a previous study, the viability of numerous cancer cell lines was assessed, including the hepatocarcinoma HepG2, gastric cancer AGS, colorectal cancer HT-29 and the breast cancer cell line MCF-7, following treatment with the C. soldanella crude extract (27). Similar effects, including a decrease in cell viability, were observed in HT-29 and HepG2 cells (27). Therefore, the aim of the present study was to evaluate the mechanism underlying any changes in HT-29 cell physiology after treatment with C. soldanella extract fractions.

Materials and methods

Sample collection and preparation. Whole-plant C. soldanella samples were collected from Gijang, Busan, Korea. A voucher specimen was deposited at the Herbarium of the Division of Marine Environment and Bioscience, Korea Maritime and Ocean University (Busan, Korea). The entire plant samples were briefly air-dried at room temperature for 1 month, ground into a fine powder using a blender and stored at -20°C.

Extraction and fractionation. The crude extract of the plant samples (500 g) was eluted in 99% ethanol for 3 h at room temperature before being filtered and concentrated three times. The concentrated crude extracts were evaporated under reduced pressure at 40°C using rotary vacuum evaporator and partitioned between H2O-methanol (9:1) and n-hexane (4.3 g). The organic layer was further partitioned into dichloromethane (DCM; 15.2 g) and ethyl acetate (2.3 g). The aqueous layer was also fractionated into n-butanol (14.6 g) and water (16.4 g). Each fraction used was completely removed using a reflux condenser and was subsequently freeze-dried for use in experiments. All solvent reagents used for extraction were of analytical grade. The DCM fraction was diluted to a final concentration of 0.2% DMSO so as not to induce toxicity. For the control, an equivalent volume of 0.2% DMSO was added to the culture medium.

Ultra-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight mass spectrometry (UPLC-ESI-Q-TOF-MS) analysis. The DCM fractions were analyzed using UPLC-ESI-Q-TOF-MS. The UPLC system (Agilent infinity 1260 series; Agilent Technologies Deutschland GmbH), with an incorporated photodiode array detector (DAD) and Impact II Q-TOF mass spectrometer (Bruker Corporation), was equipped with an ESI source that operated on the negative ion mode. A reverse phase Kinetex core-shell C18 column (100x2.1 mm, 1.7 µm, Phenomenex) was used at a flow rate of 0.5 ml/min. The mobile phase consisted of water containing 0.1% TFA (A) and 0.1% TFA containing acetonitrile (B) using the following gradient conditions: 0-1 min, 10% B; 1-4 min, 10-20% B; 4-6 min, 20-25% B; 6-8 min, 25% B; 8-9 min, 25-30% B; 9-11 min, 30% B; 11-12 min, 30-50% B; 12-14 min, 50-60% B; 14-15 min, 60-80% B; and 15-17 min, 80% B. The injection volume was 2 µl. Mass spectra in positive-ion or negative-ion mode were recorded within 20 min. The UPLC profiles of the extracts were measured using a DAD. The analyses were conducted in the negative ion mode in a mass range from m/z 50 to 1,000. The ESI source parameters were: Capillary voltage, 4.5 KV; nebulizing gas pressure, 1.5 bar; drying gas temperature, 200°C, drying gas flow, 9.0 l/min; Funnel IRF 250.0 Vpp; transfer time, 50.0 µs; and pulse prepulse storage, 2.0 µs. The MS data were analyzed using Data Analysis 4.2 software (Bruker Corporation).

Cell culture. The human colorectal HT-29 cell line (cat. no. 30038) was purchased from the Korean Cell Line Bank, Korean Cell Line Research Foundation. The STR profile of the HT-29 cell line was as follows: D3S1358, 15/17; von Willebrand factor type A, 17/19; fibrinogen alpha chain, 20/22; amelogenin, X; tyrosine hydroxylase 1, 4/9; thyroid peroxidase, 8/9; CSF1P0, 11/12; D5S818, 11/12; D1S317, 11/12; and D7S820, 10. The cells were cultured at 37°C with 5% CO2 in RPMI-1640 medium (Welgene, Inc.) supplemented with 10% FBS (Welgene, Inc.) containing 100 U/ml penicillin and 100 µg/ml streptomycin (cat no. CA005-10; GenDEPOT, LLC). The culture medium was refreshed every 2 days and the cells were subcultured for use in subsequent experiments.

Cell viability assays. Cell viability was analyzed using a EZ-Cytox Kit (cat. no. EZ-1000; DoGenBio Co., Ltd.) according to the manufacturer's protocol. Cells were seeded into 96-well plates at 4x104 cells/well and allowed to attach for 24 h. First, cell viability was examined for each fraction (hexane, DCM, ethyl acetate, butanol, water) at concentrations of 0, 25, 50 or 100 µg/ml for 24 h. Next, attached cells were treated with 0, 10, 20, 40, 60, 80 or 100 µg/ml of the DCM fraction in serum-free medium for 24 or 48 h. Subsequently, cells were incubated with the EZ-Cytox solution (100 µl/well) for 30 min at 37°C before absorbance at 450 nm was quantified using the FilterMAX F5 microplate reader (Molecular Devices LLC.). In addition, morphological cell changes were subsequently observed using a light microscope (magnification, x200; Eclipse TS100-F; Nikon Corporation).

Apoptosis assay. Apoptosis was assessed using the Muse® Annexin V and Dead Cell Kit (cat. no. MCH100105; Luminescent Corporation) according to the manufacturer's protocol. Cells were seeded into six-well plates at 1x105 cells/well and treated with 20, 40 or 80 µg/ml concentrations of the DCM fraction for 20 h. The cells were then harvested at a density of 5x104 cells/well and washed twice with PBS and stained with FITC-Annexin V and dead cell reagent for 20 min at room temperature in the dark. The percentage of apoptotic cells was determined using the Guava® Muse® Cell Analyzer (2012model; Luminescent Corporation).

Assessment of mitochondrial membrane potential (MMP). The MMP was assessed using the Muse® MitoPotential Kit (cat. no. MCH100110; Luminescent Corporation) according to the manufacturer's protocol. Cells were seeded into six-well plates at 1x105 cells/well and treated with 0, 20, 40 or 80 µg/ml concentrations of the DCM fraction for 20 h. The cells were harvested at a density of 5x104 cells/well, washed twice with PBS, stained with MitoPotential working solution containing MitoPotential dye and incubated for 20 min in a 37°C CO2 incubator. The MMP was determined using the Guava MUSE Cell Analyzer (2012 model).
**Preparation of total cell lysate.** HT-29 cells were treated with 0, 20, 40 or 80 µg/ml of the DCM fraction in serum-free medium for 24 h at 37°C. The cells were washed with PBS and lysed in M-PER Mammalian Protein Extraction Reagent (cat. no. 78501; Thermo Fisher Scientific, Inc.) containing phosphate inhibitor cocktail (cat. no. 1862495; Thermo Fisher Scientific, Inc.) and Protease/Arrest™ protease inhibitor cocktail (cat. no. 786-108; G-Biosciences; Geno Technology, Inc.) on ice for 30 min. The extracts were centrifuged at 12,000 x g for 10 min and the supernatants were subsequently used for western blotting. The mitochondrial and cytosolic fractions were extracted using a Mitochondria Isolation Kit (cat. no. 89874; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocols. Protein concentrations were measured using a BCA Protein Assay Kit (cat. no. 23225; Thermo Fisher Scientific, Inc.).

**Western blotting.** Total protein (20–40 μg protein/lane) was electrophoresed via SDS-PAGE on a 8-15% acrylamide gel and transferred onto polyvinylidene fluoride immobilon-P membranes (cat. no. MLPJHV00010; MilliporeSigma). The membranes were blocked with 1% bovine serum albumin (BSA; cat. no. A0100; GenDEPOT, LLC) in TBS with 0.1% Tween-20 (TBST; 5 mM Tris, 20 mM sodium chloride, pH 7.4) and incubated with primary antibodies (1:1,000) in 1% BSA/TBST with gentle agitation at 4°C overnight. The membranes were then washed twice for 15 min in TBST and incubated with the corresponding HRP-conjugated secondary antibodies (1:10,000) for 2 h at room temperature, before being washed again using TBST. Immunoreactive bands were detected using the WesternBright™ ECL HRP Substrate (cat. no. K12045; Advanta, Inc.) and visualized using the GeneGnome 5 (model 75000; Syngene). Differences in protein levels were determined by semi-quantifying the western blotting band densities using ImageJ software version 1.46r (National Institutes of Health).

The antibodies used were as follows: Anti-Fas (cat. no. sc-7886; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-8 (cat. no. sc-7890; rabbit; Santa Cruz Biotechnology, Inc.), anti-Bcl-2 (cat. no. sc-7382; mouse; Santa Cruz Biotechnology, Inc.), anti-Bcl-extra-large (XL; cat. no. sc-7195; rabbit; Santa Cruz Biotechnology, Inc.), anti-Bad (cat. no. sc-8044; mouse; Santa Cruz Biotechnology, Inc.), anti-Bax (cat. no. sc-7480; mouse; Santa Cruz Biotechnology, Inc.), anti-caspase-9 (cat. no. sc-7885; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-7 (cat. no. sc-6138; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-3 (cat. no. sc-7148; rabbit; Santa Cruz Biotechnology, Inc.), anti-X-linked inhibitor of apoptosis protein (XIAP; cat. no. 2045; rabbit; Cell Signaling Technology, Inc.), anti-caspase-3 (cat. no. sc-7148; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-7 (cat. no. sc-7886; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-9 (cat. no. sc-7885; rabbit; Santa Cruz Biotechnology, Inc.), anti-Bcl-2 (cat. no. sc-7382; mouse; Santa Cruz Biotechnology, Inc.), anti-Bax (cat. no. sc-7480; mouse; Santa Cruz Biotechnology, Inc.), anti-caspase-9 (cat. no. sc-7885; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-7 (cat. no. sc-6138; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-3 (cat. no. sc-7148; rabbit; Santa Cruz Biotechnology, Inc.), anti-X-linked inhibitor of apoptosis protein (XIAP; cat. no. 2045; rabbit; Cell Signaling Technology, Inc.), anti-caspase-3 (cat. no. sc-7148; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-7 (cat. no. sc-7886; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-9 (cat. no. sc-7885; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-8 (cat. no. sc-7890; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-1 (cat. no. sc-7195; rabbit; Santa Cruz Biotechnology, Inc.), anti-caspase-2 (cat. no. sc-3130; rabbit; Cell Signaling Technology, Inc.), anti-cytochrome c (cat. no. 4272; rabbit; Cell Signaling Technology, Inc.), anti-cytochrome c oxidase subunit IV (COX IV; cat. no. 4844; rabbit; Cell Signaling Technology, Inc.), anti-cyclin A (cat. no. BS-0571R; rabbit; BLOSS), anti-CDK2 (cat. no. sc-163; rabbit; Santa Cruz Biotechnology, Inc.), anti-cyclin A (cat. no. sc-7382; mouse; Santa Cruz Biotechnology, Inc.) and anti-cyclin-dependent kinase inhibitor 1 (p21; cat. no. sc-271532; rabbit; Santa Cruz Biotechnology, Inc.). Anti-β-actin (cat. no. sc-4777; mouse; Santa Cruz Biotechnology, Inc.) antibody was used as the loading control. The secondary antibodies used were HRP-conjugated anti-mouse IgG (cat. no. 7076; Cell Signaling Technology, Inc.) and anti-rabbit IgG (cat. no. 7074; Cell Signaling Technology, Inc.).

**Statistical analysis.** All data are presented as the mean ± SD of three independent experiments. Means between >2 groups were compared using one-way or two-way ANOVA followed by Bonferroni’s multiple comparison test using GraphPad Prism version 7 software (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

**Results**

Solvent fractions of C. soldanella reduce HT-29 cell viability. To determine the effects of the C. soldanella fractions on cell viability, HT-29 cells were treated with each of the five solvent fractions (n-hexane, DCM, ethyl acetate, n-butanol and water) at different concentrations (0, 25, 50 and 100 µg/ml) for 24 h, after which cell viability was examined. Cell viability was significantly decreased following treatment with the DCM fraction compared with that in the 0 µg/ml group (Fig. 1A). Therefore, the DCM fraction with the highest dose-dependent effect was selected for further study.

Reductions in the viability of HT-29 cells was confirmed following treatment with different concentrations (0-100 µg/ml) of DCM fraction for 24 and 48 h (Fig. 1B). HT-29 cell viability appeared to be decreased following DCM fraction treatment in a time- and dose-dependent manner compared with those in the 0 µg/ml group. After treatment with 0, 10, 20, 40, 60, 80 and 100 µg/ml DCM, cell viability was 100±4.7, 89.0±3.5, 74.6±6.7, 73.2±2.0, 53.5±7.1, 26.7±1.6 and 25.4±1.7% at 24h, respectively, whereas it was 100±3.4, 92.6±8.3, 57.9±6.6, 35.4±3.6, 20.2±1.6, 9.3±0.5 and 8.7±0.2% at 48 h, respectively (Fig. 1B). In addition, it was observed that the morphological changes confirmed via microscope were reduced in the same way as the results of the cell viability assay (Fig. 1C).

**DCM fraction from C. soldanella induces apoptosis in HT-29 cells.** The Annexin V and Dead Cell Kit was used to determine whether this decrease in cell viability induced by DCM fraction treatment resulted from apoptosis. The rates of early and late apoptosis were significantly increased in a dose-dependent manner following treatment with the DCM fraction compared with those in the 0 µg/ml group (Fig. 2).
The proportions of early apoptotic cells were 0.7±0.67, 38.2±1.81, 23.0±3.07 and 1.0±0.38%, whilst those of late apoptotic cells were 0±0.05, 2.1±0.40, 12.9±7.12 and 35.1±0.58%, following DCM fraction treatment at concentrations of 0, 20, 40 and 80 µg/ml, respectively.

Regarding the protein expression levels of apoptosis-related proteins, DCM fraction treatment at 40 and 80 µg/ml significantly increased the protein expression levels of Fas protein whilst significantly decreasing those of pro-caspase-8, an extrinsic signaling pathway-related protein (Fig. 3), compared with those in the 0 µg/ml group. Other intrinsic apoptosis signaling pathway-related proteins that also showed significantly decreased protein expression levels after 40 and 80 µg/ml DMC treatment were Bcl-2 and Bcl-xL, whilst those that showed significantly increased protein expression levels following 40 and 80 µg/ml DCM fraction treatment were Bad and Bax (Fig. 3). Consequently, the Bax/Bcl-2 ratio was significantly increased in the 40 and 80 µg/ml DCM fraction treatment groups compared with that in the 0 µg/ml group. In addition, 40 and 80 µg/ml DCM fraction treatment also significantly decreased the expression of pro-caspase-9, pro-caspase-7 and pro-caspase-3 levels compared with those in the 0 µg/ml group. The protein expression levels of XIAP, cIAP-1 and cIAP-2, caspase inhibitors involved in apoptosis inhibition, were significantly decreased by 40 and 80 µg/ml DCM treatment compared with those in the 0 µg/ml group. These results suggest that the treatment of HT-29 cells with DCM from C. soldanella may induce apoptosis by regulating the expression of pro-apoptotic, pre-apoptotic and caspase inhibitor proteins.

DCM fraction from C. soldanella induces MMP changes in HT-29 cells. Since MMP changes are also associated with apoptosis (29-31), the effects of DCM fraction treatment on the MMP in HT-29 cells were investigated. The proportions of live and dead cells with depolarized mitochondria were markedly increased following DCM fraction treatment compared with those in the 0 µg/ml group. The proportions of depolarized cells under MMP changes are also associated with apoptosis (29-31), the effects of DCM fraction treatment on the MMP in HT-29 cells were investigated. The proportions of live and dead cells with depolarized mitochondria were markedly increased following DCM fraction treatment compared with those in the 0 µg/ml group. The proportions of depolarized mitochondria were markedly increased following DCM fraction treatment compared with those in the 0 µg/ml group.
live cells were 5.2±0.75, 43.6±1.49, 2.9±0.21 and 1.2±0.05%, whereas the proportions of depolarized dead cells were 0.8±0.24, 10.5±1.48, 89.7±0.33 and 95.8±0.35%, at concentrations of 0, 20, 40 and 80 µg/ml, respectively (Fig. 4a). The protein expression levels of MMP-related proteins were examined using western blotting. DCM fraction treatment at 40 and 80 µg/ml significantly increased the release of cytochrome c into the cytosol from the mitochondria compared with that in the 0 µg/ml group (Fig. 4B). In addition, DCM fraction treatment also resulted in the significantly increased translocation of Bax into the mitochondria from the cytosol in a dose-dependent manner compared with the 0 µg/ml group.

**DCM from C. soldanella induces S-phase arrest in HT-29 cells.**
To determine whether decreased cell viability was associated with the cell cycle, HT-29 cell cycle progression was analyzed using a cell cycle kit following DCM fraction treatment. DCM significantly induced S-phase arrest in a dose-dependent manner compared with the 0 µg/ml group, with S-phase cell proportions of 20.7±1.8, 33.8±0.7, 39.9±5.6 and 45.3±0.2% at concentrations of 0, 20, 40 and 80 µg/ml of the DCM fraction, respectively (Fig. 5A). Subsequently, the relative protein expression levels of S-phase-related proteins were analyzed using western blotting. DCM fraction treatment at 40 and 80 µg/ml led to the significant downregulation of cyclin A, CDK2 and Cdc25A protein expression and the significant upregulation of p21 protein expression compared with those in the 0 µg/ml group (Fig. 5B).

**ESI-Q-TOF-MS analysis of DCM fraction from C. soldanella.**
UPLC-ESI-Q-TOF-MS analysis was applied to analyze the polyphenolic compounds in the DCM fraction of C. soldanella to screen for any anticancer substances. The HPLC-UV chromatogram (350 nm) and total ion current chromatogram in the DCM fraction are presented in the Fig. 6A and B. Molecular ion mass, MS/MS fragment ion mass and MS-based compound analysis data are all provided in Table I. UPLC-ESI-Q-TOF MS analysis demonstrated that the major compounds in the DCM fraction were hydroxybenzoic acid, hydrosinapinic acid and coumaric acid, which are phenolic acid derivatives, and quercetrin, which is a flavonoid quercetin derivative.

**Discussion**
The ultimate aim of discovering novel chemotherapeutic strategies is to overcome drug resistance (32). A number of studies have previously investigated the potential anticancer activity of natural compounds/products and suggested them to be promising sources of new anticancer drugs (4-13). For example, the natural compound S-adenosylmethionine has
KiM et al: dichloromethane fraction induces S-phase arrest and apoptosis

been found to exert anti-tumor properties, including reduction of cell proliferation, induction of apoptosis, autophagy and inhibition of invasion and metastasis, in various cancer cell types, such as human hepatocellular carcinoma, human breast cancer and head and neck squamous cancer cells, in previous in vitro and in vivo studies (33-36).

To date, anticancer-associated studies related to C. soldanella have revealed cytotoxic effects of methanol and chloroform extracts on the lung cancer A545 and colon cancer Co12 cell lines (26) and the anticancer effects of an 85% aqueous methanol fraction on the liver cancer cell line HepG2 (27). However, only a few studies have investigated the anticancer effects of C. soldanella.

In the present study, solvent fractions were obtained from C. soldanella, which have been previously reported to exert anticancer activity in human liver cancer cell line HepG2 (27), before an effective fraction that can exhibit anticancer effects on the colorectal cancer cell line HT-29 was selected. Following the crude extraction of C. soldanella with ethanol, the crude extracts were fractionated into n-hexane, dichloromethane, ethyl acetate, n-butanol and water. The effects of these five fractions on HT-29 cell viability were examined before the dichloromethane (DCM) fraction was selected due to its significant time- and dose-dependent effects.

Apoptosis serves a critical role in the regulation of cell development and proliferation (37,38). This process has become a target of cancer treatments due to its association with a number of different types of cancer (39,40). Two major pathways of apoptosis have been identified: i) The extrinsic death receptor pathway; and ii) the endoplasmic reticulum stress pathway and intrinsic mitochondrial apoptosis (41). To determine the effect of DCM fraction treatment on cell

Figure 3. Effects of DCM fraction treatment on the expression of apoptosis-related proteins in HT-29 cells. HT-29 cells were incubated with various concentrations of the DCM fraction for 20 h. The expression levels apoptosis-related proteins Fas, pro-caspase-8, Bcl-2, Bcl-xL, Bad, Bax, pro-caspase-9, pro-caspase-7, pro-caspase-3, XIAP, cIAP-1 and cIAP-2 were then determined by western blotting. β-actin was used as the loading control. The bands were semi-quantitatively analyzed by ImageJ software and the relative protein expression levels are presented. All results were normalized to the untreated control (0 µg/ml). Data are presented as the mean ± SD of three independent experiments. *P<0.05 vs. 0 µg/ml DCM. DCM, dichloromethane; xl, extra-large; XIAP, X-linked inhibitor of apoptosis protein; cIAP-1, cellular inhibitor of apoptosis protein-1; cIAP-2, cellular inhibitor of apoptosis protein-2.
viability and apoptosis, apoptosis and apoptosis-related protein expression levels in HT-29 cells that were treated with the DCM fraction were investigated. The results demonstrated significantly increased apoptotic rates and marked changes in the expression levels of apoptosis-related proteins in both the extrinsic and intrinsic signaling pathways. Treatment with DCM fraction increased Fas and decreased pro-caspase-8, which corresponds to the extrinsic signaling pathway. In addition, treatment with DCM fraction increased Bad and Bax, and decreased Bcl-2, Bcl-xL, pro-caspase-9, pro-caspase-7 and pro-caspase-3, which corresponds to the intrinsic signaling pathway.

The mitochondrial apoptosis pathway involves a number of components, including pre-apoptotic proteins Bcl-2 and Bcl-xL and pro-apoptotic proteins Bax and Bak (42-44). The ratio of Bax/Bcl-2 determines the direction of apoptosis regulation. An increased Bax/Bcl-2 ratio can lead to the loss of mitochondrial membrane potentials, which is an important process in the initiation of apoptosis (45). Furthermore, it has been reported that an increased Bax/Bcl-2 ratio can activate caspase-3 to in turn activate apoptosis (46,47). In the present study, caspase-3 was also markedly activated following DCM fraction treatment. Since the Bax/Bcl-2 ratio was also markedly increased with DCM fraction treatment, it was hypothesized that DCM may activate apoptosis by altering the mitochondrial membrane potential.

Apoptosis involves the regulation of a series of proteins mainly in the mitochondrial signaling pathway (48).
mitochondria maintain the cellular energy balance and regulate cell death processes (49). Cellular energy generated during mitochondrial respiration is stored as an electrochemical gradient across the mitochondrial membrane, which allows the mitochondria to induce ATP synthesis (49). Changes in the MMP are associated with apoptosis, necrosis and caspase-independent cell death processes in addition to the opening of mitochondrial transition pores, to release cytochrome c into the cytosol and initiate apoptotic and caspase cascades (31,49). In the present study, MMP changes following DCM fraction treatment led to matrix condensation and exposure of cytochrome c to the intermembrane space, which may have activated apoptosis (Fig. 4).

Numerous proteins associated with cell cycle regulation are known to be involved in apoptosis (50). In the present study, cell cycle assay was performed and the protein expression levels of several cell cycle-related proteins were investigated to determine whether apoptosis induced by DCM fraction treatment was due to cell cycle regulation in HT-29 cells. The results demonstrated that DCM fraction treatment significantly increased the proportion of cells in the S-phase. Cyclins and cyclin-dependent kinases serve important roles in cell cycle regulation, where changes in the composition of cyclin/CDK complexes can either increase or decrease cell proliferation and/or differentiation through apoptosis (51,52). Since cyclin A, CDK2 and Cdc25A serve critical roles in S-phase regulation (53,54), their protein expression levels following DCM fraction treatment were examined. The results showed marked downregulation of cyclin A, CDK2 and Cdc25A expression following DCM treatment. CDK1, p21 (Waf1/Cip1) have been previously shown to induce cell cycle arrest by inhibiting CDK activity (55,56). The results of the present study demonstrated a dose-dependent increase in p21 protein expression levels in response to DCM, which may have inhibited Cyclin A-CDK2 complex formation and contributed to cell cycle arrest between the S and G2/M phases.
It has been frequently reported that numerous compounds can exert anticancer activity independent of p53 (57-60). The tumor suppressor p53 has been found to be dysfunctional in ≥50% colorectal cancer cases (58,59). Colorectal cancer cells and tumors with p53 mutation are reported to be more aggressive and resistant to chemotherapy (60). In the present study, the HT-29 cell line is a p53 mutant cell line (genotype R273H), to which DCM exerted anticancer effects in the absence of p53. Although not conducted in the present study, anticancer effects following DCM fraction treatment are also hypothesized to be present in p53 wild-type cell lines and warrants further study.

Previous studies have reported that *C. soldanella* contains a variety of polyphenolic compounds, including flavonoids, flavonoid glycosides and phenolic acid derivatives (56,61). Molecular ion mass, MS/MS fragment ion mass and MS-based compound analysis data are all provided in Table I. UPLC-ESI-Q-TOF MS analysis demonstrated that the major compounds in the DCM fraction were hydroxybenzoic acid, hydrosinapinic acid and coumaric acid, which are phenolic acid derivatives, and quercetin, which is a flavonoid quercetin derivative. Various phenolic acids, such as coumaric acid, caffeic acid and ferulic acid, function as secondary plant metabolites (62). In particular, cinnamic acid-based phenolic acid compounds, such as coumaric acid, caffeic acid, ferulic acid and sinapinic acid, have been reported to exert anticancer activity in various colon cancer cell lines (63). Coumaric acid is reported to induce apoptosis in the colon cancer HCT-115 cell line and induce G1/S arrest in the colon cancer cell line Caco-2 (64-66). These aforementioned phenolic acids also have inhibitory activities on the proliferation of various colorectal/colon cancer cell lines (67-69).

In conclusion, to the best of our knowledge, the present study was the first to report the anticancer effects of DCM from *C. soldanella* on HT-29 colorectal cancer cells, which possibly occurred by MMP alteration, S-phase arrest and induction of apoptosis through the intrinsic/extrinsic signaling pathways. The present study also demonstrated that phenolic acid derivatives are the main components of the DCM fraction, which exerted inhibitory activities on HT-29 colorectal cancer cell by apoptosis and cell cycle arrest.

### Acknowledgements

Not applicable.

### Funding

The present study was part of the Future Fisheries Food Research Center Project, funded by the Ministry of Oceans and Fisheries (grant no. 201803932).
Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

Authors' contributions

IHK, TE and TJN conceived and designed the experiments. IHK, JYP and HJK performed the experiments. IHK, TE and HJK analyzed and interpreted the results and wrote and revised the manuscript. IHK, TE and TJN confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Rawla P, Sunkara T and Barsouk A: Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol 14: 89-103, 2019.
2. Cancer Trends Progress Report; Colorectal cancer Treatment. National Cancer Institute, 2020.
3. Xie YH, Chen YX and Fang JY: Comprehensive review of cancer: Trends Progress report; colorectal cancer Treatment. Colon Cancer Diagnosis Ther: Jun 5, 2021 (Epub ahead of print), doi: 10.1007/978-3-030-64668-4_13.
4. Pandey R, Singh PK and Shrivastava AK: Seaweeds: Potential candidates in human colon cancer therapy. Colon Cancer Diagnosis Ther: Jun 5, 2021 (Epub ahead of print), doi: 10.1007/978-3-030-64668-4_13.
5. Xie YH and Jiang Q: Roles of the polyphenol-gut microbiota interaction in alleviating colitis and preventing colitis-associated colorectal cancer. Adv Nutr 12: 546-565, 2021.
6. García-Lafuente A, Guillamón E, Villares A, Rostagno MA and Martínez JA: Flavonoids as anti-inflammatory agents: Implications in cancer and cardiovascular disease. Inflamm Res 58: 537-552, 2009.
7. Akiyama Y, Kimuma Y, Enatsu R, Mikami T, Waniuchi M and Mikuni N: Advantages and disadvantages of combined chemotherapy with curcumin and bevacizumab in patients with newly diagnosed glioblastoma: A single-institutional experience. World Neurosurg 113: e508-e514, 2018.
8. Bar-Shalom R, Bergman M, Graossman S, Azzam S, Sharvit L and Fares F: Inula viscosa extract inhibits growth of colorectal cancer cells in vitro and in vivo through induction of apoptosis. Front Oncol 9: 227, 2019.
9. Bravo L: Polyphenols: Chemistry dietary sources metabolism nutritional significance. Nutr Rev 56: 317-333, 1998.
10. Moreira H, Slezak A, Szyka A, Oszmianski J and Gasiorowski K: Antioxidant and cancer chemopreventive activities of cistus and pomegranate polyphenols. Acta Pol Pharm 74: 688-698, 2017.
11. del Mar Blanquer-Rosselló M, Hernández-López R, Roca P, Oliver J and Valle A: Resveratrol induces mitochondrial respiration and apoptosis in SW620 colon cancer cells. Biochim Biophys Acta Gen Suga 1861: 431-440, 2017.
12. Kim IH and Nam TJ: Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. Oncol Rep 39: 1516-1522, 2018.
13. Kim IH, Kwon MJ and Nam TJ: Differences in cell death and cell cycle following fucoidan treatment in high-density HT-29 colon cancer cells. Mol Med Rep 15: 4116-4122, 2017.
14. Bae CY, Hwang JS, Bae JI, Choi SC, Lim SH, Choi DG, Kim JG and Choo YS: Physiological responses of Calystegia soldanella under drought stress. J Ecol Environ 36: 255-265, 2013.
15. Bae BH: The Medicinal Plants of Korea. Korea, Kyo-Hak Publishing, Seoul, 2000.
16. Lee YS, Kwak CG and Kim NW: Nutritional characteristics of Calystegia japonica. Korean J Food Preserv 19: 619-625, 2012.
17. Takagi S, Yamaki M, Masuda K and Kubota M: Studies on the purgative drugs. IV. On the constituents of Calystegia japonica Choisy (author's transl). Yakugaku Zasshi 97: 1369-1371, 1977 (In Japanese).
18. Kim Y, Min HY, Park HJ, Lee EJ, Park EJ, Hwang HJ, Jin C, Lee YS and Lee SK: Suppressive effects of nitric oxide production and inducible nitric oxide synthase (iNOS) gene expression by Calystegia soldanella methanol extract on lipopolysaccharide-activated RAW 264.7 cells. Eur J Cancer Prev 13: 419-424, 2004.
19. Huang Z and Feng C: Experimental study on anti-inflammatory and analgesic effects of water extracts of Calystegia soldanella. Chin Arch Tradit Chin Med 6: 7, 2010.
20. Lee JI, Kim IH, Choi YH, Kim EY and Nam TJ: PTP1B inhibitor effect of alkyl p-coumarates from Calystegia soldanella. Nat Prod Commun 9: 1585-1588, 2014.
21. Sidiry ES, Ganeshan G and Lokesh AN: Antifungal activity and isomerization of octadeyl p-coumarates from Ipomoea carnea subsp. fistulosa. Nat Prod Commun 6: 1899-1892, 2011.
22. Ono M, Kanemaru Y, Yasuda S, Okawa M, Kinjo J, Miyashita H, Yokomizo K, Yoshimitsu H and Noraha T: A new resin glycoside from Calystegia soldanella and its antiviral activity towards herpes simplex virus. Chem Pharm Bull (Tokyo) 62: 839-844, 2014.
23. Ono M, Takigawa A, Kanemaru Y, Kawakami G, Kabata K, Okawa M, Kinjo J, Yokomizo K, Yoshimitsu H and Noraha T: Calysolins V-IX, resin glycosides from Calystegia soldanella and their antiviral activity toward herpes. Chem Pharm Bull (Tokyo) 62: 97-105, 2014.
24. Ono M, Kawakami G, Takigawa A, Kabata K, Okawa M, Kinjo J, Yokomizo K, Yoshimitsu H and Noraha T: Calysolins X-XIII, resin glycosides from Calystegia soldanella, and their antiviral activity toward herpes simplex virus. Chem Pharm Bull (Tokyo) 62: 839-844, 2014.
25. Ono M, Takigawa A, Muto H, Kabata K, Okawa M, Kinjo J, Yokomizo K, Yoshimitsu H and Noraha T: Antiviral activity of four new resin glycosides calysolins XIV-XVII from Calystegia soldanella against Herpes Simplex Virus. Chem Pharm Bull (Tokyo) 62: 641-648, 2015.
26. Min HY, Kim Y, Lee EJ, Hwang HJ, Park EJ and Lee SK: Cytotoxic activities of indigenous plant extracts in cultured human cancer cells. Nat Prod Sci 8: 170-172, 2002.
27. Lee JI, Kim IH and Nam TJ: Crude extract and solvent fractions of Calystegia soldanella induce GI and S phase arrest of the cancer cell line HepG2 cells. Int J Oncol 50: 414-420, 2017.
28. Ly JD, Grubb DR and Lawen A: The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 8: 115-128, 2003.
29. Gottlieb E, Armour SM, Harris MH and Thompson CB: Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ 10: 709-717, 2003.
30. Yang J, Cao L, Li Y and Liu H, Zhang M, Ma H, Wang B, Yuan X and Li Q: Gracillin isolated from Reineckea carnea induces apoptosis of A549 cells via the mitochondrial pathway. Drug Des Devel Ther 15: 233-243, 2021.
31. Christensen ME, Jansen ES, Sanchez W and Waterhouse NJ: Flow cytometry-based assays for the measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release. Methods 61: 138-145, 2013.
32. Mosca L, Pagano M, Pecoraro A, Borzacchiello L, Mele L, Cacciapuoti G, Porcelli M, Russo G and Russo A: S-Adenosyl-L-methionine overcomes a L3-mediated drug resistance in p53 deleted colon cancer cells. Int J Mol Sci 22: 103, 2021.
33. Lu SC and Mato JM: S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol 23 (Suppl 1): S73-S77, 2008.
34. Cave DD, Desiderio V, Mosca L, Ilioso CP, Mele L, Caraglia M, Cacciapuoti G and Porcelli M: S-Adenosylmethionine-mediated apoptosis is potentiated by autophagy inhibition induced by chlororquin in human breast cancer cells. J Cell Physiol 235: 1370-1383, 2018.
35. Ilissos CP, Delle Cave D, Mosca L, Pagano M, Coppola A, Mele L, Caraglia M, Cacciapuoti G and Porcelli M: S-Adenosylmethionine regulates apoptosis and autophagy in MCF-7 breast cancer cells through the modulation of specific microRNAs. Cancer Cell Int 18: 197, 2018.

36. Mosca L, Minopoli M, Pagano M, Vitiello F, Carriero MV, Cacciapuoti G and Porcelli M: Effects of S-adenosyl-L-methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms. Int J Oncol 56: 1212-1224, 2020.

37. D’Arcy MS: Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int 43: 582-592, 2019.

38. Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol 35: 495-516, 2007.

39. Pistritto G, Trisciuoglio D, Ceci C, Garufi A and D’Orazio G: Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY) 8: 603-619, 2016.

40. Goldar S, Khantiani MS, Derakhshan SM and Baradaran B: Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 16: 2129-2144, 2015.

41. Pan Y, Ye C, Tian Q, Yan S, Zeng X, Xiao C, Wang L and Wang H: miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade. Oncol Lett 15: 4337-4343, 2018.

42. Knight T, Luedtke D, Edwards H, Taub JW and Ge Y: A delicate balance-The Bcl-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol 162: 250-261, 2019.

43. Orrenius S: Mitochondrial regulation of apoptotic cell death. Toxicol Lett 149: 19-23, 2004.

44. Scorrano L and Korsmeyer SJ: Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 304: 437-444, 2003.

45. Meeran SM and Katiyar SK: Grape seed proanthocyanidins promote apoptosis in human epidermoid carcinoma A431 cells through alterations in Cdk1-Cdk-cyclin cascade, and caspase-3 activation via loss of mitochondrial membrane potential. Exp Dermatol 16: 405-415, 2007.

46. Siu WP, Pun PB, Latchoumypadane C and Boelsterli UA: Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in dicrofencan-induced hepatocyte injury: Multiple protective roles of cyclosporin A. Toxicol Appl Pharmacol 227: 451-461, 2008.

47. Ohitsuuka T, Buchsbaum D, Oliver P, Makkija S, Kimberly R and Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044, 2003.

48. Wang X, Lu X, Zhu R, Zhang K, Li S, Chen Z and Li L: Betulinic acid induces apoptosis in differentiated PC12 cells via ROS-mediated mitochondrial pathway. Neurochem Res 42: 1130-1140, 2017.

49. Estaquier J, Vallette F, Vassyliere JL and Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med Biol 942: 157-183, 2012.

50. Pucci B, Kasten M and Giordano A: Cell cycle and apoptosis. Neoplasia 2: 291-299, 2000.

51. Canaveze M, Santo L and Raje N: Cyclin dependent kinases in cancer: Potential for therapeutic intervention. Cancer Biol Ther 13: 451-457, 2012.

52. Sperka T, Wang J and Rudolph KL: DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 13: 579-590, 2012.

53. George Rosenker KM, Paquette WD, Johnston PA, Sharlow ER, Vogt A, Bakam A, Lazo JS and Wipf P: Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Ddc25B. Bioorg Med Chem 23: 2810-2818, 2015.